Watson Pharmaceuticals Inc has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for citalopram hydrobromide tablets, in the 10 mg, 20 mg and 40 mg strengths.

Citalopram hydrobromide tablets are the generic version of Forest Laboratories' Celexa, which is indicated for the treatment of depression. The Company expects to initiate shipments of the product in the near future. For the 12-months ending June 2004, Celexa had sales of approximately $1.4 billion, according to IMS Health data.

Watson Pharmaceuticals Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products.